Sign up to save your podcasts
Or
Share SSRI Deprescribing Impact on Psilocybin Facilitation
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
SSRI Deprescribing Impact on Psilocybin Facilitation
The HHS Secretary's announcement of the federal "MAHA Action Plan to Curb Psychiatric Overprescribing" has 38 million Americans asking a question they weren't asking before: what else is out there?
In this episode, Coeli breaks down what the SSRI deprescribing push actually means for people navigating this shift, and for the facilitators and aspiring facilitators working in this field. This is not a political conversation. It's a clinical one.
She covers the true scale of antidepressant use in the US, how SSRIs were designed versus how they've actually been prescribed, why psilocybin-assisted therapy is a research-backed alternative for depression, who is and isn't a good candidate, the latest neuroscience on neuroplasticity and the integration window, and what the standard of care actually requires from the people trained to hold this space.
The numbers are clear: as this conversation moves into the mainstream, the field is going to need a lot more trained facilitators.
If you're considering facilitator training, apply at entheotraining.com/apply-now-1.
Sources: PMC 2026 antidepressant prevalence study · CDC NCHS Data Brief April 2025 · KFF Health News Feb 2026 · Ward, Haslam & Prasad medRxiv 2025 · Nature May 2026 (psilocybin and neuroplasticity)
View all episodes
By Entheogen InstituteThe HHS Secretary's announcement of the federal "MAHA Action Plan to Curb Psychiatric Overprescribing" has 38 million Americans asking a question they weren't asking before: what else is out there?
In this episode, Coeli breaks down what the SSRI deprescribing push actually means for people navigating this shift, and for the facilitators and aspiring facilitators working in this field. This is not a political conversation. It's a clinical one.
She covers the true scale of antidepressant use in the US, how SSRIs were designed versus how they've actually been prescribed, why psilocybin-assisted therapy is a research-backed alternative for depression, who is and isn't a good candidate, the latest neuroscience on neuroplasticity and the integration window, and what the standard of care actually requires from the people trained to hold this space.
The numbers are clear: as this conversation moves into the mainstream, the field is going to need a lot more trained facilitators.
If you're considering facilitator training, apply at entheotraining.com/apply-now-1.
Sources: PMC 2026 antidepressant prevalence study · CDC NCHS Data Brief April 2025 · KFF Health News Feb 2026 · Ward, Haslam & Prasad medRxiv 2025 · Nature May 2026 (psilocybin and neuroplasticity)